Peptide CDMO-evaluatiecriteria: 2026 Realitycheck

Wat de 2026 Capaciteitsafbeelding vertelt het feitelijk aan een koper

Capaciteitsaankondigingen beschrijven het plan van een leverancier, geen slot dat u kunt boeken. Bachems eigen halfjaarlijkse bekendmaking maakt het onderscheid concreet: De EBIT daalde 19.1% naar CHF 54.1 miljoen, en de EBIT-marge werd gecomprimeerd 16.6% van 21.4% een jaar eerder, waarbij de opstartkosten van Gebouw K als oorzaak worden genoemd (Bachem Holding AG, ad-hoc-uitgave, 2026-07-30).

De splitsing tussen CMC Development en Commercial API laat zien waarom één enkele groeikop misleidend is. In H1 2026, CMC Development bereikte CHF 167.5 miljoen (+39.5% in lokale valuta) terwijl de commerciële API daalde naar CHF 133.0 miljoen (-19.3% LC), en Onderzoek & Specialiteiten toegevoegd CHF 25.9 miljoen (+30.5% LC) (dezelfde uitgave, 2026-07-30). De groei is niet uniform over de levenscyclus, Het segment dat een leverancier uitbreidt, vertelt u dus aan welke klanten hij prioriteit geeft.

Lees de richtlijnen op dezelfde manier. Het originele volledige jaar 2025 begeleiding ingesteld 35% naar 45% groei in lokale valuta met CAPEX boven CHF 400 miljoen voor 2026 (Bachem Holding AG, ad-hoc-uitgave, 2026-03-12), later verkleind tot 35% naar 40%. En de CEO van Bachem op het gebied van planningsbeveiliging zegt expliciet dat samenwerkingen op lange termijn “ons in staat stellen om op betrouwbare wijze de ontwikkeling en het gebruik van productiecapaciteiten te plannen” (Bachem, 2023-03-02). K's bouwen 2026 opstarten, produceert al commerciële GMP-producten naast CHF 148.4 miljoen aan H1-investeringen, is planning aan de leverancierszijde (Bachem Holding AG, ad-hoc-uitgave, 2026-07-30).

Beschouw deze cijfers dus als vragen, geen bewijs. De rest van deze gids zet ze om in zes peptide CDMO-evaluatiecriteria: beoordeling van de behoeften, technische breedte, expertise op het gebied van modificatie, analytische diepgang, communicatie en doorlooptijden, en de transitie van verkennend naar procesontwikkeling.

Beoordeling van behoeften: Wat u daadwerkelijk koopt voordat u leveranciers vergelijkt

Peptide CDMO-evaluatiecriteria werken alleen als u uw eigen programma heeft geclassificeerd, omdat stadium, schaal, modaliteit, wijzigingstraject en analytische verplichting veranderen stuk voor stuk wat een geloofwaardige leverancier moet kunnen aantonen. Kopers die beginnen met een leveranciersvergelijking vergelijken meestal marketingpagina's in plaats van mogelijkheden.

Begin met vijf vragen. Voor welke ontwikkelingsfase is het materiaal bedoeld: verkennende synthese, klinische aanbod, of commerciële GMP? Welke schaal moet de route overleven?, en moet het over het volledige bereik blijven bestaan ​​in plaats van op één punt?? Welke modaliteit is van toepassing: lineair peptide, gemodificeerd of geconjugeerd peptide, of iets dat aangrenzend is aan oligonucleotiden? Vindt de wijziging plaats op hars of in oplossing?, en gaat het om niet-natuurlijke resten of om een ​​conjugaat?? Eindelijk, wat is de analytische verplichting: uitgave van onderzoekskwaliteit, of een specificatie die zal worden ingediend en verdedigd?

De segmentmix van een leverancier is een nuttig signaal voor welke van deze markten hij wil bedienen. Het halfjaar van Bachem 2026 de resultaten rapporteerden een groepsomzet van CHF 326.4 miljoen, omhoog 4.3% in CHF en 7.3% in lokale valuta (Het halfjaar van Bachem 2026 resultaten, 2026-07-30), en de segmentmix in Bachems H1 2026 uit de openbaarmaking blijkt waar die inkomsten zich concentreren. Bachems eigen capaciteitenpositionering beschrijft volledige levenscyclus peptide- en oligonucleotide API-ondersteuning op vier GMP-gecertificeerde locaties, terwijl De syntheseplatforms van MOL Changes dekking SPPS, vloeibare fase, hybride- en fermentatieroutes over een bereik van milligram tot kilogram.

Sleutel afhaalmaaltijd: Beantwoord de vijf classificatievragen voordat u offertes aanvraagt. Fase, schaal, modaliteit, wijziging en analytische verplichting beslissen welke leveranciers überhaupt vergelijkbaar zijn.

Technische breedte: Een capaciteitsclaim lezen met de juiste oplossing

De technische mogelijkheden van Peptide CDMO zijn alleen zinvol als een leverancier deze als sequentielengte vermeldt, een chemie en een schaal. “Complexe peptiden” is geen specificatie. Vraag naar het nummer.

De praktische ladder begint met routinematige vaste-fasesynthese, wat over het algemeen tot ongeveer betrouwbaar is 30 naar 40 residuen. Buiten dat bereik, de koppelingsefficiëntie daalt scherp om sequentieafhankelijke redenen, Daarom beweegt het plafond tussen projecten, in plaats van op één vast nummer te zitten.

A 2026 Natuurchemieonderzoek naar aggregatie op hars legt het mechanisme uit: aggregatie begint doorgaans binnenin 5 naar 15 aminozuren van het harsverankeringspunt, dus C-terminale residuen oefenen de grootste invloed uit, en de fractionele aminozuursamenstelling in plaats van de exacte sequentie bepaalt grotendeels het gedrag. De mislukking is structureel, geen bedieningsfout.

Dat maakt de antwoorden meetbaar. De gedocumenteerde verbetering van de zuiverheid van de Arg-tag nam de ruwe zuiverheid op polystyreenhars van ongeveer 20% naar 41%, en een moeilijk peptide dat rond Ser10 aggregeerde, produceerde een slecht ruw product met veel deletie-onzuiverheden totdat ruggengraatbescherming werd toegepast.

Vraag dus vier dingen: welke reeksen je hebt gefaald, your longest routine length, your documented mitigation for aggregation-prone stretches (backbone protection, pseudoproline, magnetron, HFIP), and the crude purity you see before purification.

Wijzigingsexpertise: Waar de routebeslissing wordt genomen

Complex peptide modification services are not a menu of chemistries. They are the ability to choose a site of modification and defend that choice against the impurity profile it creates.

De routebeslissing staat voorop. On-resin modification adds fewer steps, but it exposes the modification to every subsequent coupling and deprotection, so side reactions accumulate into the final profile. In-solution modification after cleavage gives cleaner control over the modified species, at the cost of an extra purification and a scale-up step. Geen van beide is universeel beter; the program’s scale and the modification’s stability decide it.

Classes fail differently. Non-natural residues and N-methylation change coupling kinetics and can drive deletion sequences. Lipidation and PEGylation introduce hydrophobic or polymeric species whose removal, not whose attachment, is usually the hard part. The point at which a modification choice locks in the impurity profile is the route decision itself, not the final purification.

Ask three questions of every supplier. Which modifications do you perform in-house versus outsource, and how does that split change your analytical package? At what scale does your preferred route change? What happens to the route when the program moves from feasibility to GMP? MOL Changes’ modification portfolio states more than 300 modifying groups, including isotope labelling, N- and C-terminal modifications, glycopeptides, cyclische peptiden, biotinylation and fluorescent labelling, which is the kind of scope claim worth testing against those three questions. Bachem’s own capability positioning is a useful comparison point for how a supplier draws its in-house versus outsourced boundary.

Analytische diepgang: De criteria die beslissen over een due diligence-gesprek

Peptide analytical method development is where a supplier’s dossier stops being a certificate of analysis and becomes a control strategy. A CoA reports one lot against one specification. A control strategy explains how that specification was set, what the method can and cannot detect, and what happens when the method is transferred to your laboratory or to a GMP site.

Ask for orthogonal characterization: reversed-phase HPLC plus mass spectrometry plus a second separation that works by a mechanistically different principle, so a co-eluting impurity cannot hide behind the main peak. Ask how impurity profiling is judged against the ICH Q3A/Q3B impurity thresholds applied to peptides, where reporting begins at 0.05%, identificatie bij 0.10% en kwalificatie op 0.15% for a drug substance at a maximum daily dose of 2 g/dag of minder. The widely quoted 95% naar 98% purity by RP-HPLC is an industry convention, geen compendiale limiet; USP monographs set criteria per monograph.

Method validation should follow ik Q2(R2) as published in March 2024, which covers spectroscopic procedures and post-approval change management. Sterility testing and USP <85> bacterial endotoxins testing are separate gates: a lot can pass one and fail the other, and the Gel Clot Limit Test is the referee method in a dispute. ISO 9001:2015 en ISO 13485:2016 certify quality management systems, not peptides or APIs; Ik vraag 7 remains the GMP baseline.

Communicatie en doorlooptijden: Wat het contract feitelijk beschermt

Ask any peptide CDMO evaluation to give you three separate numbers, because they are three different commitments: the quoted lead time, the protected slot, and the realistic first-GMP-batch date. A quoted lead time is an estimate. A protected slot is a contractual reservation of manufacturing capacity. The realistic first-batch date is the one your IND milestone actually depends on, and it is the one most often left implicit.

What separates a supplier that protects your slot from one that merely describes it is what sits in writing. Four clauses carry most of the weight: the change-control notification window, the named technical contact and their stated availability, the escalation path when something slips, and the batch-record and deviation-notification obligations. Add one more question: what happens to your slot if it slips. A supplier’s own long-term contracts exist to secure its capacity planning, dat is Peptide a legitimate business interest but not the same as protecting your reservation. Bachem’s long-term follow-on peptide supply contract, signed in March 2023, commits a minimum CHF 1 billion in total order volume across 2025 naar 2029, with the customer unnamed and confidentiality agreed. That structure tells you how the supplier plans capacity; it does not tell you how it treats yours. Cem Peptide Synthesizer

Sleutel afhaalmaaltijd: Get three numbers in writing, niet één. Quoted lead time, protected slot, and realistic first-GMP-batch date. Then lock four clauses: change-control notification window, named technical contact and availability, escalation path, and deviation-notification obligations. Peptide 1

Widely circulated figures of 9 naar 18 maanden, of 18 naar 24 maanden, for CDMO engagement timelines are unconfirmed trade-source claims, not benchmarks. Build your own timeline from the committed dates the supplier puts in the contract, and treat any number you cannot trace to a signed commitment as an estimate.

Van verkennende synthese tot procesontwikkeling: Waar programma's daadwerkelijk kapot gaan

Peptide process development scale-up is where most programs lose time, and the loss rarely announces itself as a phase gate. It shows up as a sequence of small events. Feasibility synthesis at 0.1 mmol proves the sequence can be made at all. The chosen route then meets mixing, heat transfer and reagent addition rates that change the impurity profile, and an aggregation-prone sequence that behaved at bench scale can fail at 10 mmol. Analytical methods transfer next, and a method validated on a small-scale crude does not automatically hold on a larger batch. The specification set at feasibility may not be the specification that can be filed.

Three failure modes recur: aggregation and deletion impurities that surface only at scale, on-resin modifications that cannot be reproduced in solution, and method-transfer gaps discovered at the first GMP batch. Each one is cheaper to find before the route is locked.

This is also where a supplier’s structure becomes visible. A CDMO that hands work between a research group and a GMP group will answer scale-up questions in two voices. De syntheseplatforms van MOL Changes, which the company states span solid-phase and liquid-phase synthesis plus modification with in-house HPLC/MS and sterility QC, is a capability claim worth testing against exactly these three failure modes rather than accepting as a summary.

Rode vlaggen en dealbreakers: Het scheiden van herstelbare hiaten en diskwalificerende factoren

In peptide CDMO evaluation criteria, the useful split is not “good supplier versus bad supplier” but “gap I can manage versus condition that disqualifies.” The distinction is commercial, not academic: a deal-breaker cannot be fixed by a better price, while a manageable gap priced as a deal-breaker is a negotiation position rather than a technical finding.

Deal-breakers are structural. No ICH Q7 GMP evidence for the specific site that will make your material disqualifies a supplier, because ICH Q7 is the baseline expectation for API manufacture and a certificate held by a different plant does not transfer. The same applies to absent in-house orthogonal characterization, refusal to name the site and team that will run your program, no documented change-control process, and a CoA reporting one purity number with no impurity profile.

Manageable gaps look different. A longer quoted lead time with a protected slot, a modification currently outsourced behind a named partner and transfer plan, or a method needing development with a documented validation path under ICH Q2(R2) are all workable, provided the commitment is written into the contract.

Red flags: deal-breaker or manageable gap?

| Voorwaarde | Uitspraak | The question that decides it | | No ICH Q7 GMP evidence for your manufacturing site | Deal-breaker | Is the certificate for the site that will make my batch? | | No in-house orthogonal characterization | Deal-breaker | Can they characterize what they cannot see? | | Site and team unnamed | Deal-breaker | Who signs the batch record? | | No documented change-control process | Deal-breaker | What happens when a raw-material source changes? | | CoA shows one purity number, no impurity profile | Deal-breaker | What is in the other percent? | | Longer lead time, protected slot | Manageable | Is the slot contractually reserved? | | Modification outsourced, partner named | Manageable | Is there a dated transfer plan? | | Method needs development, validation path documented | Manageable | Is the ICH Q2(R2) path agreed in writing? |

Strategic announcements are not auditable capability. Bachem’s Sisslerfeld announcement commits more than CHF 500 million to a greenfield large-scale facility with commercial production expected in 2030, and the partnership details were not disclosed by agreement. That signals direction, not a qualification you can inspect today.

Hoe u deze criteria kunt gebruiken om te beslissen

Score the six dimensions against your own needs assessment, not against each other. A supplier that leads on modification breadth can still be the wrong choice if your program needs process development scale-up support and their evidence there is thin. Weight each dimension by how much it matters for your molecule and stage, then compare only like-for-like evidence.

A short procedure works better than a long one. Assign each dimension a weight that sums to 100. Request the same evidence package from every supplier: impurity profile method and limits, route-redenering, quoted lead time with the conditions attached, and the analytical methods that will transfer with the program. Then treat unanswered questions as negative evidence rather than neutral. A supplier who cannot describe how a 40-residue hydrophobic sequence is handled has told you something.

Read public disclosure correctly. Het halfjaar van Bachem 2026 results and its 2026 investment guidance, including CHF 350–400 million of planned investment and sales growth guidance of 35% naar 40% in lokale valuta (Bachem Holding AG, 2026-07-30), signal strategic direction. K's bouwen 2026 start-up signals the same. Neither is auditable evidence of technical performance on your sequence, so use them to judge where a supplier is investing, not what it can do for you.

The next step is to test these peptide CDMO evaluation criteria against a real program: talk to a technical expert about your sequence and stage, and compare capabilities on the evidence that matters.

Veelgestelde vragen

Wat moet ik een peptide CDMO vragen bij een eerste technisch gesprek?

Ask for the route, not the pitch: which synthesis platform the team would choose for your sequence and why, who owns the analytical methods, and what happens if the sequence fails at scale. ICH Q7 sets the API GMP baseline those answers sit inside, so ask which parts of the work run under it.

Is een capaciteitsuitbreiding een bewijs van capaciteit?

Nee. Announced capacity shows a company expects demand, not that the site can run your chemistry. Judge capability separately, on route selection, impurity control and the analytical package, and treat capacity as a scheduling input.

Hoe lang duurt de betrokkenheid van peptide CDMO realistisch??

Published figures vary widely and are divergent estimates, not settled numbers. Timelines depend on sequence difficulty, whether methods already exist, and queue position, so ask for a quoted lead time, a protected slot and a realistic first-GMP-batch date as three separate commitments.

Hoe vergelijk ik een CoA van twee leveranciers??

Compare the method, not just the number: which impurities were measured, against which thresholds, by which technique. ICH Q3A/Q3B impurity thresholds applied to peptides define the reporting and qualification limits, en ik Q2(R2) as published in March 2024 covers how the validating method itself is demonstrated. A CoA without method detail is not comparable.

Vervangt ISO-certificering GMP-bewijs??

Nee. ISO covers a management system; GMP evidence covers how the material was made and controlled. Ask against ICH Q7, and require endotoxin data traceable to a defined method such as USP <85> bacterial endotoxins testing.

Welke zuiverheidsspecificatie is redelijk voor een peptide in de klinische fase??

It depends on the indication, route and phase, and no single number fits every program. Ask the CDMO to justify the specification against the impurity profile and the toxicology batch rather than quoting a default, and confirm the release and stability methods are validated for it.

Hoe verandert de vraag naar GLP-1 de doorlooptijden van peptide-CDMO's??

It is tightening them, but the size of the effect is contested. Morgan Stanley’s GLP-1 market outlook puts 2025 GLP-1 sales at USD 79 billion and a base case of USD 190 miljard door 2035, terwijl Grand View Research’s peptide therapeutics forecast projects USD 294.58 miljard door 2033 bij 8.73% CAGR. A second house’s peptide market estimate is far lower, so treat the demand signal as directionally real and the magnitude as an open question.

Conclusie

The most useful shift a buyer can make is to treat reported capacity as an input to interrogate rather than as evidence of fit, and peptide CDMO evaluation criteria exist precisely to make that interrogation repeatable. Start with your own requirements, then read technical breadth at the resolution of the actual route, weigh modification and analytical depth against the chemistry you need, and test what the contract protects rather than what the brochure promises. The market’s own estimates diverge widely, with Grand View Research projecting USD 294.58 miljard door 2033 against Mordor Intelligence’s USD 70.20 miljard door 2031, a gap that reflects different market definitions as much as different forecasts. That divergence is the argument for checkpoints over narrative. It also cuts the other way on timing: capacity announced for 2030, such as Bachem’s Sisslerfeld announcement, is not capacity available to a 2026 programma. MOL Changes heeft een commercieel belang bij de kwaliteitsnormen voor peptiden.